Edge Wealth Management’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-11,000
Closed -$4.76K 87
2022
Q4
$4.76K Hold
11,000
﹤0.01% 85
2022
Q3
$5K Hold
11,000
﹤0.01% 82
2022
Q2
$5K Hold
11,000
﹤0.01% 89
2022
Q1
$7K Hold
11,000
﹤0.01% 91
2021
Q4
$7K Buy
11,000
+400
+4% +$713 ﹤0.01% 316
2021
Q3
$36K Hold
10,600
0.01% 207
2021
Q2
$40K Buy
10,600
+10,300
+3,433% +$42.6K 0.01% 207
2021
Q1
$2K Buy
+300
New +$2.66K ﹤0.01% 385

Other funds holding MTCR

Edge Wealth Management's MTCR Position: Q1 2023 in Review

Edge Wealth Management sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 11,000 shares — an estimated $4.76K sold.

Edge Wealth Management first reported a position in MTCR in Q1 2021 and held it in 8 quarters. The position peaked at $40K in Q2 2021. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Edge Wealth Management reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Edge Wealth Management sold 11,000 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $4.76K.
  • Edge Wealth Management first reported a position in Metacrine, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Edge Wealth Management's Metacrine, Inc. Common Stock position peaked at $40K in Q2 2021.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Edge Wealth Management's 13F filing for Q1 2023, filed 18 Apr 2023.